To better understand treatment preferences of patients with anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) and to estimate the relative importance of preferred treatment attributes.

gMG is a rare, chronic autoimmune disorder. Key therapeutic approaches differ among the available treatments for AChR-Ab+ gMG, but no studies on patient treatment preferences have been published to date.

US adults with a self-reported physician diagnosis of AChR-Ab+ gMG completed a web-based survey. Two object-case, best-worst scaling (BWS) exercises were analyzed. The first BWS exercise obtained preferences for a treatment profile similar to ravulizumab compared with 4 other treatment profiles (eg, similar to eculizumab, efgartigimod intravenous and subcutaneous, and zilucoplan). The second BWS exercise obtained preferences for the individual attributes used to define the treatment profiles. Profile scenarios were defined by mode of administration and dosing frequency only, followed by the addition of consistent disease control and meningococcal vaccination requirements. Additionally, the most important gMG treatment attribute was identified.